AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Resmed DRC

37.350

+0.9102.50%

Volume:639.12K

Turnover:24.07M

Market Cap:54.75B

PE:2.77

High:37.510

Open:37.420

Low:37.330

Close:36.440

Loading ...

Overview Company News Filings

Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks

McKesson Stock May Rise With PRISM Vision Holdings Acquisition

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

Simple but not easy: How to invest as Buffett intended

Morning Star AU

BSX Q4 Earnings & Revenues Top, Stock Falls on Weak Gross Margin

Reasons to Retain Inari Medical Stock in Your Portfolio for Now

Earnings optimism is back!

How to build a world-class ASX share portfolio in 2025

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

STXS Stock Gains Following the First Order for its GenesisX

GEHC Stock May Rise With $138M Investment in Cork Facility Expansion

Resmed Incorporated's Fiscal 2Q Revenue, NPAT Results Above Consensus; Jarden Research Says

MT Newswires Live

6 ASX 200 shares that could benefit from a weak Australia Dollar

ResMed's half-year FY25 results: solid growth & expanding opportunities

Resmed's Chief Legal Officer Sells Shares

MT Newswires Live

ResMed Inc. Stock Rises Monday, Outperforms Market

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/RMD.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RMD.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","market":"AU","secType":"STK","nameCN":"Resmed DRC","latestPrice":37.35,"timestamp":1741649207713,"preClose":36.44,"halted":0,"volume":639120,"delay":0,"changeRate":0.024973,"change":0.91,"floatShares":145639189,"shares":1465797180,"eps":13.506951,"lyrEps":11.073667,"pbRate":6.54,"amount":24065162.87,"amplitude":0.00494,"volumeRatio":6.942701,"dividePrice":3.221197,"prevYearClose":36.689,"fiveDayClose":37.77,"twentyDayClose":37.737},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RMD.AU\",,,,,undefined,":{"symbol":"RMD.AU","floatShares":145639189,"roa":"13.89%","roe":"25.65%","lyrEps":11.068389,"volumeRatio":6.942701,"shares":1465797180,"dividePrice":3.219662,"high":37.51,"amplitude":0.00494,"preClose":36.44,"low":37.33,"week52Low":26.807,"pbRate":"6.54","psRate":"6.97","week52High":40.661,"institutionHeld":0,"latestPrice":37.35,"committee":0.958188,"eps":13.500514030236134,"divideRate":0.085851,"volume":639120,"delay":0,"ttmEps":13.500514030236134,"open":37.42,"prevYearClose":36.689,"prevWeekClose":35.88,"prevMonthClose":37.12,"prevQuarterClose":36.689,"fiveDayClose":37.77,"twentyDayClose":37.737,"sixtyDayClose":38.196},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RMD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-12","symbol":"RMD.AU","amount":0.053,"announcedDate":"2025-01-31","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-02-13","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-20","payableDate":"2025-02-13","currency":"USD","dateTimestamp":1739278800000,"payDate":"2025-03-20"},{"date":"2024-11-06","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-10-25","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-11-07","name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-12","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730811600000,"payDate":"2024-12-12"},{"date":"2024-08-14","symbol":"RMD.AU","amount":0.053,"announcedDate":"2024-08-02","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2024-08-15","defaultRemindTime":1723593600000,"name":"Resmed DRC","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-19","payableDate":"2024-08-15","currency":"USD","dateTimestamp":1723557600000,"payDate":"2024-09-19"},{"date":"2024-05-08","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-04-26","type":"dividend","market":"AU","newRecordDate":"2024-05-09","defaultRemindTime":1715126400000,"name":"Resmed DRC","recordDate":"2024-06-13","payableDate":"2024-05-09","currency":"USD","dateTimestamp":1715090400000,"payDate":"2024-06-13"},{"date":"2024-02-07","symbol":"RMD.AU","amount":0.048,"announcedDate":"2024-01-25","type":"dividend","market":"AU","newRecordDate":"2024-02-08","defaultRemindTime":1707260400000,"name":"Resmed DRC","recordDate":"2024-03-14","payableDate":"2024-02-08","currency":"USD","dateTimestamp":1707224400000,"payDate":"2024-03-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RMD.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-08-19","recordDate":"2020-08-20","paymentDate":"2020-09-24","value":0.039,"currency":"USD"},{"executeDate":"2020-11-11","recordDate":"2020-11-12","paymentDate":"2020-12-17","value":0.039,"currency":"USD"},{"executeDate":"2021-02-10","recordDate":"2021-02-11","paymentDate":"2021-03-18","value":0.039,"currency":"USD"},{"executeDate":"2021-05-12","recordDate":"2021-05-13","paymentDate":"2021-06-17","value":0.039,"currency":"USD"},{"executeDate":"2021-08-18","recordDate":"2021-08-19","paymentDate":"2021-09-23","value":0.042,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RMD.AU\",pageSize:16,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509237277","title":"Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2509237277","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509237277?lang=en_us&edition=fundamental","pubTime":"2025-02-06 01:15","pubTimestamp":1738775700,"startTime":"0","endTime":"0","summary":"In a bold move to hold Mexico, Canada and China accountable for illegal immigration and drug trafficking, President Donald Trump issued an executive order last Saturday, threatening extensive tariffs on imports from these countries. The order was followed by counter-retaliations and other measures, all of which have heightened trade tensions between the United States and its key trading partners, with potential implications for global markets and international relations.In such a situation, medical technology companies, particularly, may face soaring production costs, ultimately resulting in higher prices for healthcare service providers and patients. Additionally, potential supply chain disruptions could delay the availability of critical medical products, including surgical instruments, diagnostic equipment and life-saving devices like pacemakers and insulin pumps. This situation is leaving equity investors uncertain about whether to withdraw their funds from the sector.Trump's Tarif","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trump-tariffs-threaten-medtech-3-171500181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0070302665.USD","LU2089283258.USD","BK4196","BK4588","LU1116320737.USD","RMD","LU2008162690.USD","LU0211331839.USD","RMD.AU","LU0158827948.USD","LU0072461881.USD","BK4533","IE00BFXG1179.USD","LU0496365809.HKD","HIMS","IE00BQXX3C00.GBP","LU0265550946.USD","BK4548","LU2111349929.HKD","LU2468319806.SGD","IE00BQXX3D17.EUR","LU0158827781.USD","LU2089984988.USD","LU0162691827.USD","BK4566","LU0320765489.SGD","LU1989764748.USD","IE00B3T34201.USD","LU0976567544.SGD","BK4504","LU1989771016.USD","LU2089284900.SGD","BK4567","LU1291159041.SGD","LU2028103732.USD","BK4082","LU2271345857.HKD","LU0211326755.USD","LU1116320901.HKD","LU2177674079.SGD","BK4585","LU0265550359.USD","IE00BQXX3F31.USD","LU1571399168.USD","LU1983299246.USD","IE000M9KFDE8.USD","LU0208291251.USD","LU1989764664.SGD","LU2023251221.USD","LU0211326839.USD","MDT"],"gpt_icon":1},{"id":"2509237270","title":"McKesson Stock May Rise With PRISM Vision Holdings Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2509237270","media":"Zacks","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509237270?lang=en_us&edition=fundamental","pubTime":"2025-02-06 00:58","pubTimestamp":1738774680,"startTime":"0","endTime":"0","summary":"McKesson Corporation MCK recently announced that it has signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC , a premier provider of general ophthalmology and retina management services, from Quad-C.McKesson is likely to purchase an 80% stake in PRISM Vision Holdings for approximately $850 million, while physicians will continue to retain a 20% interest.Following the announcement, shares of the company closed flat at $603.3 on Tuesday. In the past six months, MCK shares have lost 1.7% against the industry’s 5.7% growth. The S&P 500 increased 15.6% in the same time frame.The acquisition of a controlling stake in PRISM Vision Holdings positions McKesson as a leader in the growing specialty eye care market. This strategic move enhances its portfolio in ophthalmology, diversifies revenue streams, and strengthens its long-term specialty care infrastructure. By addressing increasing demand in a niche healthcare segment, McKesson demonstrates a commitm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mckesson-stock-may-rise-prism-165800635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0965508806.USD","LU1267930490.SGD","LU0211327993.USD","BK4533","LU0048573561.USD","LU0868494708.USD","BK4567","LU0122379950.USD","LU0162691827.USD","LU1934455194.USD","LU0965509101.SGD","LU0006061336.USD","LU1267930813.SGD","LU2008162690.USD","LU1506573853.SGD","BK4585","LU1934455863.HKD","LU0240878834.USD","LU0942090050.USD","LU2764263203.CNY","LU1037948541.HKD","LU0965509010.AUD","LU0211328371.USD","LU2089984988.USD","LU0251142724.SGD","MASI","LU1061106388.HKD","LU1057294990.SGD","RMD","LU1037948897.HKD","LU0965509283.SGD","LU0205193047.USD","LU0742534661.SGD","SG9999001440.SGD","LU2324357040.USD","CAH","BK4588","LU2177674079.SGD","LU1267930227.SGD","LU1880398554.USD","RMD.AU","LU0205194284.USD","LU0868494617.USD","LU2764263039.SGD","LU1880398471.USD","LU1023059063.AUD","LU1430594728.SGD","LU1934455277.USD","LU2112291526.USD","MCK","BK4082"],"gpt_icon":0},{"id":"2509782237","title":"Here's Why You Should Retain Ecolab Stock in Your Portfolio Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2509782237","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509782237?lang=en_us&edition=fundamental","pubTime":"2025-02-06 00:57","pubTimestamp":1738774620,"startTime":"0","endTime":"0","summary":"Ecolab Inc.ECL has been gaining from its solid product portfolio. The optimism, led by a solid third-quarter 2024 performance, along with continued focus on research and development, is expected to contribute further. However, macroeconomic concerns persist.This Zacks Rank #3  stock has rallied 6.5% in the past six months compared with theindustry’s 0.1% growth. The S&P 500 Composite has increased 15.6% during the same time frame.The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $70.65 billion. It projects 12.2% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 0.79%.Strong Q3 Results:Ecolab’s solid third-quarter 2024 results buoy optimism. The company registered a robust year-over-year uptick in its bottom line and growth in its organic revenues. Reven","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-retain-ecolab-stock-165700075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1880398554.USD","LU2211814178.USD","LU2322448957.HKD","LU1712237335.SGD","LU0006061336.USD","LU2092937221.SGD","GB00BDT5M118.USD","LU0211327993.USD","SG9999001440.SGD","ECL","LU0240877869.USD","LU1267930227.SGD","LU0154236417.USD","LU2125909759.SGD","LU2177674079.SGD","LU2322448791.USD","BK4548","LU1623119135.USD","LU0162691827.USD","LU2764262908.HKD","LU0792757196.USD","LU0211328371.USD","LU2272731600.USD","MASI","LU2008162690.USD","BK4597","LU0323239441.USD","RMD","LU1923621640.USD","LU2089279066.USD","LU2720916845.USD","LU2125909593.SGD","LU2125910336.SGD","LU2433249047.HKD","LU2125909916.SGD","LU2764263203.CNY","LU1923622291.USD","LU2764263039.SGD","LU1992135472.HKD","LU0310800965.SGD","LU1880398471.USD","LU0323240290.USD","CAH","LU1267930490.SGD","RMD.AU","LU0052756011.USD","LU0205193047.USD","LU0310799852.SGD","BK4082","LU0128525689.USD","BK4109"],"gpt_icon":0},{"id":"2509732555","title":"Simple but not easy: How to invest as Buffett intended","url":"https://stock-news.laohu8.com/highlight/detail?id=2509732555","media":"Morning Star AU","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509732555?lang=en_us&edition=fundamental","pubTime":"2025-02-06 00:00","pubTimestamp":1738771200,"startTime":"0","endTime":"0","summary":"That’s what we’ll tackle today.I propose we start by looking for three things. These are not the only ways to potentially find good companies trading at fair or good prices. They might not even be the best. But they are, I would argue, among the simplest to start working with.Two simple criteria for sustainable earnings growthEarnings per share growth can come from a few different sources. It could come from selling more of the products and services you already sell. It could come from entering new markets and selling new products and services. It could also come from raising the price you charge customers.With the aim of keeping things simple, I am going to focus on selling more of the products and services already being sold. To do this, I am going to look at two main things: 1) the likelihood of growing demand for these products and services and 2) the strength of the company’s competitive position.The second point is important because a growing market that is showering its incumben","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.morningstar.com.au/insights/personal-finance/260206/simple-but-not-easy-how-to-invest-as-buffett-intended","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"morningstar_stock","symbols":["BK7501","BK7007","RMD.AU"],"gpt_icon":0},{"id":"2509384042","title":"BSX Q4 Earnings & Revenues Top, Stock Falls on Weak Gross Margin","url":"https://stock-news.laohu8.com/highlight/detail?id=2509384042","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509384042?lang=en_us&edition=fundamental","pubTime":"2025-02-05 22:12","pubTimestamp":1738764720,"startTime":"0","endTime":"0","summary":"Boston Scientific CorporationBSX posted fourth-quarter 2024adjusted earnings per share  of 70 cents, up 27.3% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 7.7% and also exceeded the company’s adjusted earnings per share guidance range of 64-66 cents per share.Find the latest EPS estimates and surprises on ZacksEarnings Calendar.Full-year adjusted EPS of $2.51 rose 22.4% from the year-ago figure. It also exceeded the Zacks Consensus Estimate by 2%. It also surpassed the full-year adjusted EPS guidance of $2.45 to $2.47.Revenues in the fourth quarter totaled $4.56 billion, up 22.4% year over year on a reported basis and 23.1% on an operational basis . Organic growth, adjusted for foreign currency fluctuations and certain recent acquisitions and divestments, was 19.5%.The top line surpassed the Zacks Consensus Estimate by 3.4% and exceeded the company’s forecast of 16.5% reported growth and 15% on an organic basis.Full-year total revenues were $16.75 billion, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bsx-q4-earnings-revenues-top-141200449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAH","RMD.AU","RMD","BSX"],"gpt_icon":0},{"id":"2509286702","title":"Reasons to Retain Inari Medical Stock in Your Portfolio for Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2509286702","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509286702?lang=en_us&edition=fundamental","pubTime":"2025-02-05 19:57","pubTimestamp":1738756620,"startTime":"0","endTime":"0","summary":"Inari Medical, Inc.NARI is well-poised for growth on the back of a huge market opportunity for its products and its commitment to understanding the venous system. However, the company’s dependency on the adoption of its products is concerning.Shares of this Zacks Rank #3  company have gained 68.3% in the past six months compared with theindustry’s 7.2% growth. The S&P 500 Index has risen 15.6% in the same time frame.NARI, with a market capitalization of $4.66 billion, is a commercial-stage medical device company. It seeks to develop products for treating and changing the lives of patients suffering from venous diseases.The company’s negative earnings yield of 0.2% compares favorably with the industry’s . It delivered a trailing four-quarter average earnings surprise of 24.77%.Inari Medical has positioned itself as a leader in the treatment of venous thromboembolism  through its innovative ClotTriever and FlowTriever products. With a significantly underpenetrated market and a growing de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/reasons-retain-inari-medical-stock-115700689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2008162690.USD","BK4567","INGN","BK4588","BK4548","LU0052756011.USD","LU0128525689.USD","LU0211328371.USD","LU0154236417.USD","SG9999001440.SGD","LU0072461881.USD","BK4082","CAH","LU0211327993.USD","LU0390134368.USD","LU0006061336.USD","BK4504","RMD","NARI","LU0162691827.USD","LU1880398554.USD","RMD.AU","LU0310800965.SGD","BK4175","LU1267930490.SGD","LU0310799852.SGD","LU0792757196.USD","LU1571399168.USD","LU1880398471.USD","LU1267930813.SGD","LU1267930227.SGD","BK4585","LU0889566641.SGD","LU2177674079.SGD"],"gpt_icon":0},{"id":"2509447448","title":"Earnings optimism is back!","url":"https://stock-news.laohu8.com/highlight/detail?id=2509447448","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509447448?lang=en_us&edition=fundamental","pubTime":"2025-02-05 14:18","pubTimestamp":1738736339,"startTime":"0","endTime":"0","summary":"The February results season will soon be in full swing. As I traditionally like to point out: every season has its specific character. This time will be no different.But results seasons are rarely guided by earnings reports only. Events over the weekend past have reminded investors US policy decisions will be part of the mix that impacts on share prices this year.Irrespective, most market updates released locally last week saw share prices weaken in the aftermath, including for the two companies that issued financial results, Credit Corp  and ResMed .Last year’s August season proved a rather underwhelming experience, generating 37% in misses --well above average-- and only 27% of beats, marking the worst milestone for corporate results in Australia post 2013, when FNArena started gathering such stats.Shares in Zip Co, for example, are now down more than -29% since disappointing the market, though some of that weakness is US import tariffs related.With no disasters or major downgrades e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/earnings-optimism-is-back","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/earnings-optimism-is-back","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7021","BK7124","CTT","AX1.AU","BK7002","FPH","HLS.AU","XAO.AU","BK4193","BK7153","LLC.AU","PME.AU","BK4539","XJO.AU","CTT.AU","IPD.AU","BK4548","KGN.AU","MYR.AU","ASG","BK7029","ORG","CCP.AU","ORG.AU","RMD.AU","ASG.AU","BK7140","BK7016","BK7503","BK4567","BK4077","BK4212","ZIP.AU","BK7507","BK7143","WTC.AU","ZIP","BK4084","PMV.AU","AZJ.AU","MDR.AU","XKO.AU","REA.AU","LU2177674079.SGD","BK7121","FPH.AU","PME","BK7093","RMD","BK7501"],"gpt_icon":0},{"id":"2509460988","title":"How to build a world-class ASX share portfolio in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509460988","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509460988?lang=en_us&edition=fundamental","pubTime":"2025-02-05 02:09","pubTimestamp":1738692540,"startTime":"0","endTime":"0","summary":"Building a world-class ASX share portfolio in 2025 isn't about chasing the latest trends or speculating on unproven stocks. Instead, it is about focusing on high-quality businesses, paying a fair pric","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/05/how-to-build-a-world-class-asx-share-portfolio-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IVV.AU","BK7067","BK7508","RMD.AU","VOO","BK4581","BK4585","BK4534","NDQ.AU","BK4588","BK7007","BK7511","BK4559","FDN","BK4550","CSL.AU","BK7501"],"gpt_icon":0},{"id":"2508452896","title":"Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2508452896","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508452896?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:15","pubTimestamp":1738678500,"startTime":"0","endTime":"0","summary":"NEW YORK and MELBOURNE, Australia, Feb. 04, 2025  -- Incannex Healthcare Inc. , , a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment ofAlison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea  Clinical Advisory Board where she will represent ResMed.“Incannex’s newly formed clinical advisory board and the appointment of Dr. Wimms underscore our continued dedication to innovation in the field of OSA and transforming patient treatment outcomes,” said Joel Latham,Incannex's President and Chief Executive Officer. “We are thrilled to welcome Dr. Wimm’s expertise to our IHL-42X clinical advisory board. This marks an exciting step in fostering collaboration as we advance our global Phase 2/3 ‘RePOSA’ clinical study in OSA.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incannex-healthcare-appoints-alison-wimms-141500950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4167","IH","BK4588","BK7007","BK4097","RMD","BK7094","HCSG","BK4082","SEC.AU","LU2008162690.USD","BK4563","BK4567","BK4585","IXHL","BK4510","RMD.AU","BK4548","AHI","BK7501","BK4137","LU2177674079.SGD","BK4504","AHI.AU","BK7024","BK4085"],"gpt_icon":0},{"id":"2508452608","title":"STXS Stock Gains Following the First Order for its GenesisX","url":"https://stock-news.laohu8.com/highlight/detail?id=2508452608","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508452608?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:18","pubTimestamp":1738675080,"startTime":"0","endTime":"0","summary":"Stereotaxis, Inc. STXS, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, recently received its first order for the latest generation robotic system, GenesisX, from a pioneering European hospital.The latest development is in line with Stereotaxis’ focus on broadening the adoption of robotics across endovascular interventions.GenesisX is the latest iteration of Stereotaxis' Robotic Magnetic Navigation technology, which has been praised for its precision and efficiency in surgical procedures. It obtained CE Mark in Europe in 2024 and has been submitted to the FDA for 510 clearance in the United States. The first firm order placed for GenesisX is a critical milestone achieved before the full commercial launch. Accordingly, we expect the latest development to bolster investor confidence and maintain the upward momentum in STXS' share price in the coming days.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stxs-stock-gains-following-first-131800689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","LU2008162690.USD","STXS","BK4167","BK4139","BK4082","BK4548","BK4585","OMCL","BK4567","BK4588","LU2177674079.SGD","VCYT","RMD.AU","RMD"],"gpt_icon":0},{"id":"2508523384","title":"GEHC Stock May Rise With $138M Investment in Cork Facility Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2508523384","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508523384?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:34","pubTimestamp":1738672440,"startTime":"0","endTime":"0","summary":"GE HealthCare Technologies Inc. GEHC recently announced a $138 million investment to expand its manufacturing facility in Cork, Ireland. This initiative will boost the production of imaging contrast media, a critical component in diagnostic procedures, and strengthen GEHC's global supply chain to meet growing healthcare demands.The new state-of-the-art facility on the grounds of the existing site is likely to enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand.Following the announcement, shares of the company closed flat at $87.51 on Monday. In the past six months, GEHC shares have gained 7.4% compared with the industry’s 15.7% growth. The S&P 500 increased 17.7% in the same time frame.To meet this rising demand, GE HealthCare is expanding its Carrigtohill facility with a new 3000m production area. The expansion will include advanced equipment such as solution preparation vessels, powder handling systems, a new filli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gehc-stock-may-rise-138m-123400813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4175","LU2764262908.HKD","BK4548","LU1267930813.SGD","LU2764263039.SGD","LU0792757196.USD","LU1267930227.SGD","LU1267930490.SGD","LU1571399168.USD","BK4567","LU0205194284.USD","LU0211327993.USD","CAH","LU0205193047.USD","GEHC","RMD","LU0052756011.USD","LU0162691827.USD","LU0240877869.USD","LU1880398554.USD","LU0889566641.SGD","LU2177674079.SGD","LU0211328371.USD","SG9999001440.SGD","LU0124676726.USD","LU0006061336.USD","LU0072461881.USD","LU0310800965.SGD","LU0154236417.USD","LU2720916845.USD","LU0689626769.HKD","BK4082","LU2008162690.USD","LU0128525689.USD","RMD.AU","LU0310799852.SGD","LU2764263203.CNY","BK4504","BK4585","BK4588","LU1880398471.USD","MASI","LU0240878834.USD"],"gpt_icon":0},{"id":"2508887534","title":"Resmed Incorporated's Fiscal 2Q Revenue, NPAT Results Above Consensus; Jarden Research Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2508887534","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508887534?lang=en_us&edition=fundamental","pubTime":"2025-02-04 13:28","pubTimestamp":1738646881,"startTime":"0","endTime":"0","summary":"Resmed Incorporated  reported \"solid results\" for the fiscal second quarter, driven by strong device sales in the US, Jarden Research said in a Jan.31 note.Revenue for the period reached $1.282 billion, a 10.3% year-on-year increase, though it was 0.3% below Jarden's estimate of $1.285 billion and 1% but ahead of consensus at $1.27 million, Jarden said.Net profit after tax came in at $358.3 million, up 29.2% year-on-year, 0.3% below Jarden's estimate of $359.5 million, but 4.4% above consensus of $343.3 million, Jarden added.Jarden sees further improvement in the company's gross margin in the second half of the fiscal.The broker also expects the $2 million foreign exchange impact to turn neutral in the third quarter of the fiscal.While the company's freight has stabilized, it is too early to determine if they could provide any upside, the broker said.Jarden Research has an overweight rating and a price target of AU$36.60 on Resmed Incorporated.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RMD","RMD.AU"],"gpt_icon":0},{"id":"2508488959","title":"6 ASX 200 shares that could benefit from a weak Australia Dollar","url":"https://stock-news.laohu8.com/highlight/detail?id=2508488959","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508488959?lang=en_us&edition=fundamental","pubTime":"2025-02-04 12:59","pubTimestamp":1738645164,"startTime":"0","endTime":"0","summary":"With the S&P/ASX 200 Index (ASX: XJO) and many ASX 200 shares on the recovery today, there's undoubtedly more than a few investors who will be on the hunt for bargains. And comapnies that are in line ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/04/6-asx-200-shares-that-could-benefit-from-a-weak-australia-dollar/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7001","XJO.AU","BK7153","BK7511","RMD.AU","XKO.AU","XAO.AU","BK7064","BK7041","BK7063","BK7007","CSL.AU","QBE.AU","BK7034","BK7067","AMC.AU","ALD.AU","JBH.AU","BXB.AU","BK7501","BK7508","BK7065","WES.AU","COH.AU"],"gpt_icon":1},{"id":"2508483938","title":"ResMed's half-year FY25 results: solid growth & expanding opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2508483938","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508483938?lang=en_us&edition=fundamental","pubTime":"2025-02-04 12:43","pubTimestamp":1738644202,"startTime":"0","endTime":"0","summary":"ResMed’s  half-year FY25 results reflect a company that is not only thriving in its core business but is also strategically positioned to capitalise on future growth opportunities.The company is currently at the forefront of respiratory healthcare innovation with a market capitalisation of $59 billion at $39 per share. The share price, which has risen 33 per cent over the past year, materially outperformed the ASX 100’s 9.9 per cent gain over the same period, indicating growing investor confidence in the firm’s trajectory.ResMed delivered impressive growth across key metrics for the first half of the 2025 financial year, underscoring sound fundamentals and operational performance.While ResMed recorded US$4.69 billion in sales for FY24, up from US$4.22 billion in FY23, the company is forecast to achieve US$5.25 billion in FY25.ResMed’s improving margins and steady growth underpin its valuation. Using a 12-year average price-to-earnings ratio  of 30 times FY24 EPS, the company’s valuatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/resmed-s-half-year-fy25-results-solid-growth-expanding-opportunities","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/resmed-s-half-year-fy25-results-solid-growth-expanding-opportunities","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["PER.AU","FPH.AU","BK7104","BK4567","LU2177674079.SGD","PER","BK4588","BK4082","BK4504","BK7501","LU2008162690.USD","RMD.AU","BK7007","RMD","BK4548","BK4585","TAM.AU","BK7096"],"gpt_icon":0},{"id":"2508718761","title":"Resmed's Chief Legal Officer Sells Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2508718761","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508718761?lang=en_us&edition=fundamental","pubTime":"2025-02-04 06:49","pubTimestamp":1738622944,"startTime":"0","endTime":"0","summary":"Resmed (ASX:RMD) Chief Legal Officer Michael Rider sold 64 common shares in the company in the US for about $15,515 in total, according to a Tuesday filing with the Australian bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","XJO.AU","BK7007","BK4504","LU2177674079.SGD","BK4567","LU2008162690.USD","BK4588","RMD.AU","BK7501","XKO.AU","RMD","XAO.AU","BK4082","BK4548"],"gpt_icon":0},{"id":"2508157176","title":"ResMed Inc. Stock Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2508157176","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508157176?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:56","pubTimestamp":1738619760,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of ResMed Inc.  rallied 1.85% to $240.55 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.76% to 5,994.57 and Dow Jones Industrial Average  falling 0.28% to 44,421.91.ResMed Inc. closed 8.55% short of its 52-week high of $263.05, which the company reached on January 30th.Trading volume  eclipsed its 50-day average volume of 826,669.Data source: Dow Jones Market Data, FactSet. Data compiled February 3, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","RMD.AU"],"gpt_icon":0}],"pageSize":16,"totalPage":13,"pageCount":7,"totalSize":200}]}}